Several other brokerages also recently issued reports on CYNO. Northland Securities reissued an outperform rating and set a $60.00 price objective on shares of Cynosure in a research report on Thursday, February 16th. Northcoast Research raised shares of Cynosure from a sell rating to a neutral rating in a research report on Tuesday, February 14th. Maxim Group downgraded shares of Cynosure from a buy rating to a hold rating and set a $66.00 price objective on the stock. in a research report on Tuesday, February 14th. Zacks Investment Research downgraded shares of Cynosure from a hold rating to a sell rating in a research report on Monday, January 9th. Finally, TheStreet raised shares of Cynosure from a hold rating to a buy rating in a research report on Wednesday, January 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $57.88.
Cynosure (NASDAQ:CYNO) opened at 66.00 on Wednesday. The firm has a market cap of $1.61 billion, a P/E ratio of 110.00 and a beta of 1.65. The company’s 50 day moving average is $61.02 and its 200 day moving average is $50.59. Cynosure has a 52-week low of $38.93 and a 52-week high of $66.65.
Cynosure (NASDAQ:CYNO) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.03. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The company had revenue of $122.10 million for the quarter, compared to the consensus estimate of $119.97 million. During the same period last year, the firm posted $0.42 EPS. Cynosure’s revenue for the quarter was up 19.2% on a year-over-year basis. Equities research analysts forecast that Cynosure will post $1.56 EPS for the current fiscal year.
Your IP Address:
Several hedge funds have recently modified their holdings of CYNO. Royal Bank of Canada increased its stake in shares of Cynosure by 52.6% in the second quarter. Royal Bank of Canada now owns 39,430 shares of the company’s stock valued at $1,918,000 after buying an additional 13,594 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Cynosure by 18.2% in the third quarter. Advisory Services Network LLC now owns 15,410 shares of the company’s stock valued at $785,000 after buying an additional 2,370 shares during the last quarter. Algert Global LLC increased its stake in shares of Cynosure by 37.6% in the third quarter. Algert Global LLC now owns 17,620 shares of the company’s stock valued at $898,000 after buying an additional 4,812 shares during the last quarter. Eagle Boston Investment Management Inc. increased its stake in shares of Cynosure by 0.7% in the third quarter. Eagle Boston Investment Management Inc. now owns 93,645 shares of the company’s stock valued at $4,770,000 after buying an additional 696 shares during the last quarter. Finally, 1st Global Advisors Inc. purchased a new stake in shares of Cynosure during the third quarter valued at $642,000.
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024271/cynosure-inc-cyno-downgraded-by-aegis-to-hold.html
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.